Autologous Tumor Vaccine Plus Polysaccharide-derived Delta Inulin Adjuvant

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** An autologous cancer vaccine composed of tumor cell lysate extracted from a patient’s tumor and formulated with a delta inulin polysaccharide adjuvant, with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous tumor vaccine plus polysaccharide-derived delta inulin adjuvant, the autologous tumor-associated antigens (TAAs) may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the patient's tumor cells, which results in tumor cell lysis. The adjuvant may enhance the anti-tumor immune response.

**Synonyms:** - Autologous Tumor Vaccine Plus Adjuvant Advax RadVax